Citations

Mayo Clinic

Clear

2121 citation(s) found for "Ma, Julie".

Positive Association of Farm or Rural Residence with Acute Myeloid Leukemia Incidence in a Cohort of Older Women
Sinner, Penny J., Cerhan, James R. , Folsom, Aaron R. , Ross, Julie A. , Cerhan, James R

Cancer Epidemiology, Biomarkers & Prevention | March 21, 2006 | Volume: 14 | Issue: 10 | Pages: 2446-2448

10.1158/1055-9965.epi-05-0363 | PMID 16214930 Get It

AbstractThe etiology of acute myeloid leukemia (AML) is relatively unknown. Incidence rates are highest in the agricultural Midwest region compared with other regions of the United States. Many studies have examined the relationship between farming and leukemia, but most have mainly focused on men. We examined the potential association between farm or rural residence and AML in the Iowa Women's Health Study. In 1986, 37,693 women who were free of prior cancer completed a lifestyle and health questionnaire, which included a question on the place of residence. Women were subsequently followed until 2002 for cancer incidence; 79 women developed AML during the time period. Women who lived on a farm at baseline were more likely (relative risk, 1.91; 95% confidence interval, 1.19-3.05) to develop AML compared with women who did not live on a farm. Further, women who reported living on a farm or in a rural area were twice as likely (relative risk, 2.38; 95% confidence interval, 1.33-4.26) to develop AML compared with women who lived in a city with a population of >10,000 people. These results provide evidence that women who live on farms or rural areas are at an increased risk of AML.
Estrogen Bioactivation, Genetic Polymorphisms, and Ovarian Cancer
Sellers, Thomas A. , Schildkraut, Joellen M. , Pankratz, V. Shane , Vierkant, Robert A. , Fredericksen, Zachary S., Cunningham, Julie M. , Taylor, William, Liebow, Mark , McPherson, Carol, Hartmann, Lynn C. , Adjei, Araba A., Olson, Janet E. , Pal, Tuya , Vierkant, Robert A

Cancer Epidemiology, Biomarkers & Prevention | March 21, 2006 | Volume: 14 | Issue: 11 | Pages: 2536-2543

10.1158/1055-9965.epi-05-0142 | PMID 16284375 Get It

Abstract Recent experimental evidence has shown that catechol estrogens can be activated through metabolism to form depurinating DNA adducts and thereby initiate cancer. Limited data are available regarding this pathway in epithelial ovarian cancer. We conducted a case-control study of 503 incident epithelial ovarian cancer cases at the Mayo Clinic in Rochester, MN, and Jacksonville, FL, and a 48-county region in North Carolina. Six hundred nine cancer-free controls were frequency matched to the cases on age, race, and residence. After an interview to obtain data on risk factors, a sample of blood was collected for DNA isolation. Subjects were genotyped for seven common single nucleotide polymorphisms in four genes involved in catechol estrogen formation (CYP1A1 and CYP1B1) or conjugation (COMT and SULT1A1). Data were analyzed using logistic regression, stratified by race, and with adjustment for design factors and potential confounders. None of the individual genotypes were significantly associated with ovarian cancer risk. However, an oligogenic model that considered the joint effects of the four candidate genes provided evidence for an association between combinations of these genes and ovarian cancer status (P = 0.015). Although preliminary, this study provides some support for the hypothesis that low-penetrance susceptibility alleles may influence risk of epithelial ovarian cancer.
Universal Influenza Vaccination: The Time to Act Is Now
Grow, Robert W., Mair, Julie Samia, Radonovich, Lewis J. , Mair, Michael

Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science | March 17, 2006 | Volume: 4 | Issue: 1 | Pages: 20-40

10.1089/bsp.2006.4.20 | PMID 16545022 Get It

Prospective Study of Survival Outcomes in Non-Hodgkin's Lymphoma Patients With Rheumatoid Arthritis
Endo, Justin , Puumala, Susan E. , Aoun, Patricia, Black, Natalie A., O’Dell, James R., Stoner, Julie A., Boilesen, Eugene, Bast, Martin, Bergman, Debra, Ristow, Kay M., Ooi, Melissa , Mikuls, Ted R. , Armitage, Jamés O. , Habermann, Thomas M.

Journal of Clinical Oncology | March 7, 2006 | Volume: 24 | Issue: 10 | Pages: 1597-1602

10.1200/jco.2005.04.6227 | PMID 16520462 Get It

Purpose Although preliminary studies suggest that non-Hodgkin's lymphoma (NHL) complicating rheumatoid arthritis (RA) may be a clinically distinct entity compared with that occurring in the general population, studies examining the impact of antecedent RA on survival are limited. In this prospective study, we examined the association of RA with survival in patients with NHL. Patients and Methods Using two large lymphoma registries, we identified patients with evidence of RA preceding NHL. Survival in RA patients was compared with that of controls using proportional hazards regression, adjusting for the effects of age, sex, lymphoma diagnosis-to-treatment lag time, calendar year, International Prognostic Index score, and NHL grade. Results The frequency of NHL subtypes was similar in RA patients (n = 65) and controls (n = 1,530). Compared with controls, RA patients with NHL had similar overall survival (hazard ratio [HR] = 0.95; 95% CI, 0.70 to 1.30) but were at lower risk of lymphoma progression or relapse (HR = 0.41; 95% CI, 0.25 to 0.68) or death related to lymphoma or its treatment (HR = 0.60; 95% CI, 0.37 to 0.98), but were more than twice as likely to die from causes unrelated to lymphoma (HR = 2.16; 95% CI, 1.33 to 3.50). Conclusion RA is associated with improved NHL-related outcomes, including a 40% reduced risk of death occurring as a result of lymphoma or its treatment and approximately a 60% lower risk of lymphoma relapse or progression compared with non-RA controls. However, the survival advantage gained in RA from the acquisition of lymphomas with favorable prognoses is negated through an increased mortality from other comorbid conditions.
Effects of a γ-secretase inhibitor in a randomized study of patients with Alzheimer disease
Siemers, Eric , Quinn, Joseph F. , Kaye, Jeffrey , Farlow, Martin R. , Porsteinsson, Anton P. , Tariot, Pierre N. , Zoulnouni, P., Knopman, David S., Satterwhite, Julie, Gonzales, Celedon, May, Patrick C. , Galvin, James E. , Holtzman, David M. , Dean, Ralph A. , Quinn, Joseph F

Neurology | February 27, 2006 | Volume: 66 | Issue: 4 | Pages: 602-604

10.1212/01.wnl.0000198762.41312.e1 | PMID 16505324 Get It

An exploration of listener strategies in the lexical segmentation of hypokinetic dysarthric speech
Berger, Stephanie von, Caviness, John N., Edwards, Brian, Liss, Julie , Adler, Charles H.

The Journal of the Acoustical Society of America | October 17, 2005 | Volume: 100 | Issue: 3 | Pages: 2573-2573

10.1121/1.417341 Get It

This investigation examined listener transcriptions of phrases produced by speakers with mild to severe hypokinetic dysarthria to examine individual strategies for the identification of word boundaries in connected speech. It was hypothesized that the most efficient listeners would use syllabic strength information to guide their parsing of the continuous acoustic stream. Six-hundred transcribed phrases (10 listeners ×60 phrases) were coded independently by two judges to identify (1) correct word transcriptions, (2) evidence of accurate lexical parsing, regardless of exact word identification, and (3) the proportions of accurate parsing of strong and weak syllable word onsets. Linear regression analysis of the group data revealed that correct segmentation of strong syllable word onsets predicted listener performance on segmenting weak syllable word onsets [R=0.805, F(1,29)=51.440, p<0.001]. Despite a wide range of listener performance on ``words correct,'' individual strategies for perceptual segmentation were evident only in the transcriptions for the most severe speaker. In this case, the poorest listeners exhibited disproportionate difficulty with the segmentation weak syllable word onsets. Results suggest that a listener's ability to use syllabic strength information in lexical parsing determines, in part, their ability to recognize word onsets. [Work supported by NIDCD, NIH.]
Fruits and Vegetables and Ovarian Cancer Risk in a Pooled Analysis of 12 Cohort Studies
Koushik, Anita , Anderson, Kristin E. , Arslan, Alan A. , Brandt, Piet A. van den , Buring, Julie E. , Cerhan, James R. , Colditz, Graham A. , Fraser, Gary E. , Freudenheim, Jo L. , Goldbohm, R. Alexandra, Hankinson, Susan E. , Koenig, Karen L. , Larsson, Susanna C. , Leitzmann, Michael F. , McCullough, Marjorie L. , Miller, Anthony B. , Patel, Alpa V. , Rohan, Thomas E. , Schatzkin, Arthur, Smit, Ellen, Zhang, Shumin M., Smith‐Warner, Stephanie A. , Hunter, David J. , Spiegelman, Donna , Beeson, W. Lawrence , Genkinger, Jeanine M. , Hankinson, Susan E. , Willett, Walter C. , Wolk, Alicja , Cerhan, James R , Koushik, Anita , Arslan, Alan A , Colditz, Graham A , Larsson, Susanna C , McCullough, Marjorie L

Cancer Epidemiology, Biomarkers & Prevention | September 20, 2005 | Volume: 14 | Issue: 9 | Pages: 2160-2167

10.1158/1055-9965.epi-05-0218 | PMID 16172226 Get It

AbstractBecause fruits and vegetables are rich in bioactive compounds with potential cancer-preventive actions, increased consumption may reduce the risk of ovarian cancer. Evidence on the association between fruit and vegetable intake and ovarian cancer risk has not been consistent. We analyzed and pooled the primary data from 12 prospective studies in North America and Europe. Fruit and vegetable intake was measured at baseline in each study using a validated food-frequency questionnaire. To summarize the association between fruit and vegetable intake and ovarian cancer, study-specific relative risks (RR) were estimated using the Cox proportional hazards model, and then combined using a random-effects model. Among 560,441 women, 2,130 cases of invasive epithelial ovarian cancer occurred during a maximum follow-up of 7 to 22 years across studies. Total fruit intake was not associated with ovarian cancer risk—the pooled multivariate RR for the highest versus the lowest quartile of intake was 1.06 [95% confidence interval (95% CI), 0.92-1.21; P value, test for trend = 0.73; P value, test for between-studies heterogeneity = 0.74]. Similarly, results for total vegetable intake indicated no significant association (pooled multivariate RR, 0.90; 95% CI, 0.78-1.04, for the highest versus the lowest quartile; P value, test for trend = 0.06; P value, test for between-studies heterogeneity = 0.31). Intakes of botanically defined fruit and vegetable groups and individual fruits and vegetables were also not associated with ovarian cancer risk. Associations for total fruits and vegetables were similar for different histologic types. These results suggest that fruit and vegetable consumption in adulthood has no important association with the risk of ovarian cancer.
Phase I/II Study of Galiximab, an Anti-CD80 Antibody, for Relapsed or Refractory Follicular Lymphoma
Czuczman, Myron S., Thall, Aron D., Younes, Anas , Emmanouilides, Christos, Miller, Thomas P. , Moore, Joseph O., Leonard, John P. , Gordon, Leo I. , Sweetenham, John , Alkuzweny, Baha, Finucane, Deborah M., Leigh, Bryan R., Witzig, Thomas E. , Vose, Julie M. , Gordon, Leo I

Journal of Clinical Oncology | June 30, 2005 | Volume: 23 | Issue: 19 | Pages: 4390-4398

10.1200/jco.2005.09.018 | PMID 15994148 Get It

PurposeThis multicenter, dose-escalation study evaluates the safety, pharmacokinetics, and efficacy of galiximab (anti-CD80 monoclonal antibody) in patients with relapsed or refractory follicular lymphoma.Patients and MethodsPatients had follicular lymphoma that had relapsed or failed to respond to primary therapy; the majority (90%) presented with stage III or IV disease. Four weekly intravenous infusions of galiximab were administered at doses of 125, 250, 375, or 500 mg/m2.ResultsThirty-seven patients received galiximab treatment and were evaluated for safety; 35 were assessable for response. Antibody infusions were safe and well tolerated with no dose-limiting toxicities. A total of 22 (60%) of 37 patients experienced adverse events related to galiximab. All but one of the events were grade 1 or 2; the most common were fatigue, nausea, and headache. Cytopenias were rare; only one patient experienced anemia and febrile neutropenia, which were unrelated to galiximab and resolved after treatment. No patient developed antigaliximab antibody formation. The mean serum half-life ranged from 13 to 24 days. The overall response rate was 11% (two complete responses and two partial responses). Time to best response was delayed (months 3, 6, 9, and 12). Twelve patients (34%) maintained stable disease. Nearly half of all patients (49%) had a decrease in indicator lesions. Two responders remain on study without progression (22 and 24.4 months).ConclusionThe favorable safety profile of galiximab and evidence of single-agent biologic activity and dose-dependent pharmacokinetics support further evaluation of galiximab as a treatment for follicular lymphoma, possibly in combination with other lymphoma therapies.
Cancer Patients' and Patient Advocates' Perspectives on a Novel Information Source: A Qualitative Study of The Art of Oncology, When the Tumor Is Not the Target
Vickers, Kristin S. , Hathaway, Julie, Clark, Matthew M. , Britt, Teresa, Looker, Sherry, Johnson, Phaedra, Loprinzi, Charles L. , Patten, Christi A.

Journal of Clinical Oncology | June 17, 2005 | Volume: 23 | Issue: 18 | Pages: 4013-4020

10.1200/jco.2005.12.029 | PMID 15961756 Get It

Pregnancy-Associated Plasma Protein-A Is Involved in Matrix Mineralization of Human Adult Mesenchymal Stem Cells and Angiogenesis in the Chick Chorioallontoic Membrane
Jadlowiec, Julie, Dongell, Diana, Smith, Jason D. , Conover, Cheryl A. , Campbell, Phil G.

Endocrinology | May 26, 2005 | Volume: 146 | Issue: 9 | Pages: 3765-3772

10.1210/en.2004-1351 | PMID 15919757 Get It